Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127818 | 0.83 | SMN1; SMN2 (0.57) | CYP3A4CA1CA2 | |
| SCHEMBL611537 | 0.82 | SIGMAR1 (0.48) | SIGMAR1CYP3A4CA1CA2MAPT | |
| SCHEMBL611075 | 0.81 | EPHX2 (0.46) | GLSSIGMAR1EPHX1CYP3A4EPHX2 | |
| SCHEMBL10237702 | 0.80 | SIGMAR1 (0.41) | SIGMAR1EPHX1CYP3A4CA1CA2 | |
| SCHEMBL2167695 | 0.79 | CYP3A4 (0.43) | SIGMAR1EPHX1CYP3A4CA1CA2 | |
| SCHEMBL10237700 | 0.79 | SIGMAR1 (0.43) | GLSSIGMAR1EPHX1CYP3A4EPHX2 | |
| SCHEMBL237780 | 0.78 | PTGES (0.45) | SIGMAR1EPHX1EPHX2MAPTATM | |
| SCHEMBL10235830 | 0.78 | SMN1; SMN2 (0.43) | EPHX1EPHX2 | |
| SCHEMBL2151236 | 0.78 | CA1 (0.45) | SIGMAR1EPHX1CYP3A4CA1CA2 | |
| SCHEMBL232874 | 0.77 | PTGES (0.46) | SIGMAR1EPHX1CYP3A4MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| CN-101917980-B | Amine derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2013-12-11 | — | — | CN | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| CN-101917980-A | Amine derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2010-12-15 | — | — | CN | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GLS 2318/4885SIGMAR1 1415/4885EPHX1 2145/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GLS 2318/4885SIGMAR1 1415/4885EPHX1 2145/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GLS 2318/4885SIGMAR1 1415/4885EPHX1 2145/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GLS 2318/4885SIGMAR1 1415/4885EPHX1 2145/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | GLS 2318/4885SIGMAR1 1415/4885EPHX1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.